VivoSeq
Other

Neonatal Abstinence Syndrome

9

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Neonatal Abstinence Syndrome is an early-stage landscape with 9 programs across 4 companies. The most active players are Merck & Co., Novartis, Hikma Pharmaceuticals LLC. 4 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

82/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2H

Hikma Pharmaceuticals LLC

2 programs

ApprovedBoehringer Ingelheim logo

Boehringer Ingelheim

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

19

clinical trials

Completed14 · 74%
Terminated3 · 16%
Active, not recruiting1 · 5%
Unknown status1 · 5%

Clinical Trials

Trial Activity

19 trials

Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
Active, not recruiting·TThe Cooper Health System·Phase 4·NCT03092011·69 enrolled
Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome
Completed·UUniversity of New Mexico·Phase 4·NCT02851303·61 enrolled
Treatment of Neonatal Abstinence Syndrome
Completed·—·Phase 4·NCT01723722·40 enrolled
Buprenorphine for the Treatment of Neonatal Abstinence Syndrome
Completed·TThomas Jefferson University·Phase 1·NCT00521248·60 enrolled
The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels
Completed·—·Phase 3·NCT03097484·38 enrolled
Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women
Completed·SStanford University·Phase 2·NCT01965704·196 enrolled
The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome
Completed·—·N/A·NCT01754324·20 enrolled
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
Completed·IIndiana University·Phase 4·NCT04298853·17 enrolled
Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
Completed·TThomas Jefferson University·Phase 3·NCT01452789·63 enrolled
Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome
Completed·UUniversity of Tennessee Medical Center·Phase 2·NCT03670160·25 enrolled
Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)
Completed·PPediatrix·Phase 2·NCT01708707·29 enrolled
Improving Outcomes in Neonatal Abstinence Syndrome
Completed·TTufts Medical Center·Phase 3·NCT01958476·117 enrolled
Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00510016·80 enrolled
Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines
Completed·TThomas Jefferson University·Phase 1·NCT01671410·11 enrolled
A Randomized Control Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants
Completed·YYale University·Preclinical·NCT04419857·39 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)